Holocene Advisors
RVMD icon

Holocene Advisors’s Revolution Medicines RVMD Stock Holding History

Holocene Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-316,600
Closed -$13.8M – 873
2024
Q4 		$13.8M Buy
+316,600
New +$16M 0.04% 276

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Holocene Advisors's RVMD Position: Q2 2026 in Review

Holocene Advisors reduced its Revolution Medicines (RVMD) stake by 45% in Q2 2026, selling an estimated $162M and leaving 1,359,269 shares worth $255M. The position accounts for 0.57% of the portfolio, ranked #39.

Holocene Advisors first reported a position in RVMD in Q1 2023 and has held it in 14 quarters since. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Holocene Advisors held 1,359,269 shares of Revolution Medicines worth $255M as of Q2 2026.
  • Holocene Advisors sold 1,109,375 Revolution Medicines shares in Q2 2026, an estimated $162M.
  • Revolution Medicines made up 0.57% of Holocene Advisors's portfolio in Q2 2026, its #39 holding.
  • Holocene Advisors first reported a position in Revolution Medicines in Q1 2023 and has held it in 14 quarters since.
  • 693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.